Research Topics
| Peter J NeumannSummaryAffiliation: Tufts Medical Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
A strategic plan for integrating cost-effectiveness analysis into the US healthcare systemPeter J Neumann
Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, 800 Washington St, 063, Boston, MA 02111, USA
Am J Manag Care 14:185-8. 2008....
Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residentsPeter J Neumann
Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
Health Econ 21:238-51. 2012....- FDA actions against health economic promotions, 2002-2011Peter J Neumann
Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts 02111, USA
Value Health 15:948-53. 2012.... - Therapies for advanced cancers pose a special challenge for health technology assessment organizations in many countriesPeter J Neumann
Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, USA
Health Aff (Millwood) 31:700-8. 2012..Worldwide, we demonstrate that health technology assessment organizations are struggling with cancer's "exceptionalism.".. - Cancer therapy costs influence treatment: a national survey of oncologistsPeter J Neumann
Center for the Evaluationof Value and Risk in Health, Institute for Clinical Researchand Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, USA
Health Aff (Millwood) 29:196-202. 2010..The results also support educating physicians about cost-effectiveness and how to communicate with patients regarding cost... - Is the United States ready for QALYs?Peter J Neumann
Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, USA
Health Aff (Millwood) 28:1366-71. 2009..S. health care system. Strict adherence to a QALY approach is likely to prove unacceptable in the United States, but a more flexible use of QALYs could be beneficial... - Costing and perspective in published cost-effectiveness analysisPeter J Neumann
Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, Massachusetts 02111, USA
Med Care 47:S28-32. 2009..Questions linger about what cost components to include under a "societal" perspective, as well as how to value resources... - Medicare's national coverage decisions for technologies, 1999-2007Peter J Neumann
Institute for Clinical Research and Health Policy Studies, at Tufts Medical Center in Boston, Massachusetts, USA
Health Aff (Millwood) 27:1620-31. 2008.... - Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implementPeter J Neumann
Center for Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
Health Aff (Millwood) 30:2329-37. 2011..For the foreseeable future, they are likely to remain the exception as drug companies pursue payment models unconnected to data collection or performance assessment... 
Measuring the value of public health systems: the disconnect between health economists and public health practitionersPeter J Neumann
Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA 02111, USA
Am J Public Health 98:2173-80. 2008..g., social justice and reassurance value). Academic researchers evaluating the economics of public health investments should increase focus on the working needs of public health professionals...- Low-value services in value-based insurance designPeter J Neumann
Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, MA 02111, USA
Am J Manag Care 16:280-6. 2010..To identify potentially low-value services for inclusion in value-based insurance design (VBID) programs and to discuss challenges involved in incorporating such information... - Do drug formulary policies reflect evidence of value?Peter J Neumann
Department of Health Policy and Management and Center for Risk Analysis, Harvard School of Public Health, Boston, MA 02115, USA
Am J Manag Care 12:30-6. 2006..To investigate the extent to which preferred drug lists and tiered formularies reflect evidence of value, as measured in published cost-utility analyses (CUAs)... - Growth and quality of the cost-utility literature, 1976-2001Peter J Neumann
Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, MA 02115, USA
Value Health 8:3-9. 2005..This study updates and expands our previous work, which examined CUAs through 1997... - Do oncologists believe new cancer drugs offer good value?Eric Nadler
Dana Faber Cancer Institute Harvard Medical School, Boston, MA, USA
Oncologist 11:90-5. 2006..Oncologists play a pivotal role in treatment decisions, yet it is unclear whether they perceive high-cost new treatments to offer good value or how therapeutic costs factor into their treatment recommendations... - Can we better prioritize resources for cost-utility research?Peter J Neumann
Harvard School of Public Health, Boston, MA 02115, USA
Med Decis Making 25:429-36. 2005.... - Trends in the measurement of health utilities in published cost-utility analysesCarmen A Brauer
Harvard Center for Risk Analysis, Harvard School of Public Health, Boston, MA, USA
Value Health 9:213-8. 2006..tufts-nemc.org/cearegistry; previously at http://www.hsph.harvard.edu/cearegistry), and documents recent changes in methods used for utility weight elicitation... - The adoption of cost-effectiveness acceptability curves in cost-utility analysesLisa M Meckley
Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts 02111, USA
Med Decis Making 30:314-9. 2010..g., life-years or quality-adjusted life-years gained)... - Quality of clinical and economic evidence in dossier formulary submissionsFernando Colmenero
Harvard School of Public Health, Boston, MA, USA
Am J Manag Care 13:401-7. 2007..To investigate the quality and completeness of clinical and economic data in dossiers submitted by drug companies to a health plan using Academy of Managed Care Pharmacy guidelines (the Format) for formulary submissions... - Medicare and cost-effectiveness analysisPeter J Neumann
Department of Health Policy and Management and the Center for Risk Analysis, Harvard School of Public Health, Boston, USA
N Engl J Med 353:1516-22. 2005 - Cost-effective diagnostic cardiovascular imaging: when does it provide good value for the money?Hansel J Otero
Department of Radiology, Tufts Medical Center and Tufts University School of Medicine, Boston, MA 02111, USA
Int J Cardiovasc Imaging 26:605-12. 2010..The studies available have, in general, favorable cost-effectiveness profiles with major determinants relating to being compared against observation, medical or no intervention instead of other imaging tests... - 30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvementPeter J Neumann
The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, USA
Pharmacoeconomics 27:861-72. 2009..The results highlight that there are many opportunities for efficient healthcare investment, among pharmaceutical and non-pharmaceutical interventions, just as there are many investments that are inefficient... - A bibliometric review of cost-effectiveness analyses in the economic and medical literature: 1976-2006Dan Greenberg
Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, USA
Med Decis Making 30:320-7. 2010..Despite the proliferation of CEA research, there has been no detailed study focusing on the bibliometric properties of this literature... - Medicare's national coverage determinations in diagnostic radiology: examining evidence and setting limitsHansel Javier Otero
Department of Radiology, Institute for Clinical Research and Health Policy Studies, Boston, MA 02111, USA
Acad Radiol 19:1060-5. 2012..To systematically review and summarize the Center for Medicare and Medicaid Services (CMS) national coverage determination (NCDs) pertaining diagnostic imaging technologies from 1999 through 2010... - The arrival of economic evidence in managed care formulary decisions: the unsolicited request processPeter J Neumann
Department of Policy and Decision Sciences, Harvard School of Public Health, Boston, Massachusetts 02115, USA
Med Care 43:27-32. 2005..This article describes the unsolicited request process and its potential impact on the use of economic evidence in formulary decisions... - Challenges ahead for federal technology assessmentPeter J Neumann
Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts New England Medical Center, MA, USA
Health Aff (Millwood) 26:w150-2. 2007..Efforts are also needed to prioritize research, to communicate it to decision-makers, to involve stakeholders in the process, and to include cost-effectiveness information... - Does adjusting for health-related quality of life matter in economic evaluations of cancer-related interventions?Dan Greenberg
The Center for the Evaluation of Value and Risk in Health, The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
Expert Rev Pharmacoecon Outcomes Res 11:113-9. 2011..We investigated the extent to which adjusting for health-related quality of life (HRQoL) alters incremental cost per life-year gained ratios, and the implications for reimbursement decisions... - US FDA Modernization Act, section 114: uses, opportunities and implications for comparative effectiveness researchPeter J Neumann
Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, USA
Pharmacoeconomics 29:687-92. 2011.... - Drug company advertising in medical journals about the health-economic advantages of their products for 2000-2006 versus 1990-1999Jennifer A Palmer
Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, 800 Washington Street, 063, Boston, MA 02111, USA jpalmer tuftsmedicalcenter org
J Manag Care Pharm 14:749-55. 2008..We previously investigated the promotional claims made by pharmaceutical companies about the economic advantages of their prescription products in print advertisements in 6 leading medical journals from 1990-1999... - A framework for assessing the value of diagnostic imaging in the era of comparative effectiveness researchG Scott Gazelle
Department of Radiology, Institute for Technology Assessment, Massachusetts General Hospital, 101 Merrimac St, 10th Floor, Boston, MA 02114 4724, USA
Radiology 261:692-8. 2011.... - Does preventive care save money? Health economics and the presidential candidatesJoshua T Cohen
Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts New England Medical Center, Boston, USA
N Engl J Med 358:661-3. 2008 - When does quality-adjusting life-years matter in cost-effectiveness analysis?Richard H Chapman
Program on the Economic Evaluation of Medical Technology, Harvard Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts 02115, USA
Health Econ 13:429-36. 2004.... - A review of the costs and cost effectiveness of interventions in chronic kidney disease: implications for policyJoseph Menzin
Boston Health Economics, Inc, Waltham, MA, USA
Pharmacoeconomics 29:839-61. 2011..In order to realize these cost savings, efforts will be required to promote and effectively implement changes in treatment practices... - Medicare's enduring struggle to define "reasonable and necessary" carePeter J Neumann
Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, USA
N Engl J Med 367:1775-7. 2012..In today's fiscal environment, "reasonable and necessary" warrants a closer look... - Cost-utility analyses of diagnostic laboratory tests: a systematic reviewChihui Fang
Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA 02111, USA
Value Health 14:1010-8. 2011..To review and evaluate the literature of cost-utility analyses (CUAs) regarding diagnostic laboratory testing... - Decision analytic models for Alzheimer's disease: state of the art and future directionsJoshua T Cohen
Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts New England Medical Center, Boston, MA, USA
Alzheimers Dement 4:212-22. 2008.... - Cost-utility analyses in orthopaedic surgeryCarmen A Brauer
Harvard Center for Risk Analysis, Harvard School of Public Health, 718 Huntington Avenue, Boston, MA 02115, USA
J Bone Joint Surg Am 87:1253-9. 2005..We critically reviewed the literature on orthopaedic cost-utility analysis to determine which subspecialty areas are represented, the cost-utility ratios that have been utilized, and the quality of the present literature... - Economic evaluation in the US: what is the missing link?Peter J Neumann
Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Care Policy, Tufts New England Medical Center, Boston, Massachusetts, USA
Pharmacoeconomics 24:1163-8. 2006..However, a more likely outcome is the ongoing indirect use of cost-effectiveness information... - When is critical care medicine cost-effective? A systematic review of the cost-effectiveness literatureDaniel Talmor
Department of Anesthesia, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Crit Care Med 34:2738-47. 2006..Cost-effectiveness analyses (CEAs) have become increasingly common to aid decisions about the allocation of scarce healthcare resources... - Medicare's national coverage decisions, 1999-2003: quality of evidence and review timesPeter J Neumann
Harvard School of Public Health in Boston, Massachusetts, USA
Health Aff (Millwood) 24:243-54. 2005..Decisions referred to the external Medicare Coverage Advisory Committee (MCAC) have averaged eight months longer than non-MCAC decisions... - Economic messages in prescription drug advertisements in medical journalsPeter J Neumann
Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis Harvard School of Public Health, Boston, Massachusetts 02115, USA
Med Care 40:840-5. 2002..Our objectives were to examine how often prescription drug advertisements in leading medical journals contain economic messages, and to determine the types of promotional claims made and whether supporting evidence is provided... - Accuracy, risk and the intrinsic value of diagnostic imaging: a review of the cost-utility literatureHansel J Otero
Department of Radiology, Tufts Medical Center, 800 Washington Street, Boston, MA 02111, USA
Acad Radiol 19:599-606. 2012..The aim of this study was to systematically review the reporting of the value of imaging unrelated to treatment consequences and test characteristics in all imaging-related published cost-utility analyses (CUAs) in the medical literature... - Cost-effectiveness of PET in the diagnosis of Alzheimer diseasePamela M McMahon
Institute for Technology Assessment, Massachusetts General Hospital, Zero Emerson Place, Suite 2H, Boston, MA 02114, USA
Radiology 228:515-22. 2003..CONCLUSION: PET may have high diagnostic accuracy, but adding it to the standard diagnostic regimen at AD clinics would yield limited, if any, benefits at very high costs... - Migraine frequency and health utilities: findings from a multisite surveyJeffrey S Brown
Department of Ambulatory Care and Prevention, Harvard Medical School Harvard Pilgrim Health Care, Boston, MA, USA
Value Health 11:315-21. 2008..Assess the relationship between migraine frequency and health utility... - The effect of immediate reading of screening mammograms on medical care utilization and costs after false-positive mammogramsKate A Stewart
Department of Health Care Policy, 180 Longwood Avenue, Boston, MA 02115, USA
Health Serv Res 42:1464-82. 2007..To investigate whether decreased anxiety associated with immediate reading of screening mammograms resulted in lower downstream utilization and costs among women with false-positive mammograms... - Emerging lessons from the drug effectiveness review projectPeter J Neumann
Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts New England Medical Center, Boston, Massachusetts, USA
Health Aff (Millwood) 25:W262-71. 2006.... - When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncologyDan Greenberg
Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA 02111, USA
J Natl Cancer Inst 102:82-8. 2010..Because we found only modest improvement in the quality of studies, we suggest that journals provide specific guidance for reporting CUA and assure that authors adhere to guidelines for conducting and reporting economic evaluations... - Regression analysis on the variation in efficiency frontiers for prevention stage of HIV/AIDSMaki S Kamae
Division of Medical Statistics, Graduate School of Medicine, Kobe University, Japan
J Med Econ 14:187-93. 2011.... - Does Medicare have an implicit cost-effectiveness threshold?James D Chambers
Health Economics Research Group, Brunel University, Uxbridge, UK
Med Decis Making 30:E14-27. 2010..Despite the huge cost of the program, the Centers for Medicare and Medicaid Services (CMS) has maintained a policy that cost-effectiveness is not considered in national coverage determinations (NCDs)... - What can we learn from the U.S. expanded end-stage renal disease bundle?James D Chambers
The Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies Tufts Medical Center, Boston, MA, United States Electronic address
Health Policy 110:164-71. 2013..Bundled payment policies offer opportunities and challenges. Their success will be determined not only by impacts on cost containment, but also to the extent they encourage high quality care... - Evidence-based and value-based formulary guidelinesPeter J Neumann
Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts, USA
Health Aff (Millwood) 23:124-34. 2004..This paper describes the guidelines, reviews progress to date, and analyzes several critical issues for the future... - Association between preference-based health-related quality of life and asthma severityMarilyn L Moy
Division of Pulmonary and Critical Care Medicine and Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Ann Allergy Asthma Immunol 92:329-34. 2004..International guidelines have been developed to guide medical management according to asthma severity defined by lung function and symptom frequency... - Why don't Americans use cost-effectiveness analysis?Peter J Neumann
Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, MA 02115, USA
Am J Manag Care 10:308-12. 2004..This paper examines the resistance to CEA in the United States and explores ways in which to advance the field... - Delays in publication of cost utility analyses conducted alongside clinical trials: registry analysisDan Greenberg
Harvard Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, 718 Huntington Avenue, Boston, MA 02115, USA
BMJ 328:1536-7. 2004 - Twenty years of cost-effectiveness analysis in medical imaging: are we improving?Hansel J Otero
Department of Radiology, Brigham and Women s Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115, USA
Radiology 249:917-25. 2008..S. Panel on Cost-effectiveness in Health and Medicine recommendations affected CEA studies in which imaging technologies were evaluated... - Using decision analysis to better evaluate pediatric clinical guidelinesJoshua T Cohen
Tufts Medical Center, Center for the Evaluation of Value and Risk CEVR, Boston, Massachusetts, USA
Health Aff (Millwood) 27:1467-75. 2008..It is particularly useful for pediatric research, where randomized controlled trials are often unavailable and infeasible. Policymakers should incorporate decision analysis into comparative effectiveness research and clinical guidelines... - Valuing children's health: a comparison of cost-utility analyses for adult and paediatric health interventions in the USJoseph A Ladapo
Harvard Medical School and Harvard Graduate School of Arts and Sciences, Boston, Massachusetts, USA
Pharmacoeconomics 25:817-28. 2007.... - Quality-adjusted life years: how useful in medico economic studiesCarmen A Brauer
Program on the Economic Evaluation of Medical Technology, Harvard Center for Risk Analysis, Harvard School of Public Health, Boston, MA, USA
Fundam Clin Pharmacol 19:603-7. 2005..The purpose of this paper is to highlight some of the issues surrounding the use of QALYs and to encourage researchers to present their methodology in a clear and transparent way... - FDA actions against misleading or unsubstantiated economic and quality-of-life promotional claims: an analysis of warning letters and notices of violationKate A Stewart
Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, 7218 Huntington Avenue, Boston, MA 02115, USA
Value Health 5:390-7. 2002..More guidance may be needed to ensure appropriate use of these claims in drug promotions... - Potentially avoidable hospitalizations among Medicare beneficiaries with Alzheimer's disease and related disordersPei Jung Lin
Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
Alzheimers Dement 9:30-8. 2013..Individuals with Alzheimer's disease and related disorders (ADRD) have more frequent hospitalizations than individuals without ADRD, and some of these admissions may be preventable with proactive outpatient care... - What's more dangerous, your aspirin or your car? Thinking rationally about drug risks (and benefits)Joshua T Cohen
Tufts New England Medical Center, Boston, Massachusetts, USA
Health Aff (Millwood) 26:636-46. 2007..We discuss the need for the Food and Drug Administration to compare risks and benefits quantitatively, consistently, and explicitly... - Do HEDIS measures reflect cost-effective practices?Peter J Neumann
Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts 02115, USA
Am J Prev Med 23:276-89. 2002..Our study objectives were to examine the cost-effectiveness evidence for the clinical practices underlying HEDIS 2000 measures and to develop a list of practices not reflected in HEDIS that have evidence of cost effectiveness... - Direct-to-consumer advertising and shared liability for pharmaceutical manufacturersMichelle M Mello
Department of Health Policy and Management, Harvard School of Public Health, 677 Huntington Ave, Boston, Mass 02115, USA
JAMA 289:477-81. 2003 - Dialysis facility ownership and epoetin dosing in hemodialysis patients: a medical economic perspectiveJoshua T Cohen
Institute for Clinical Research and Health Policy Studies, Tufts-New England Medical Center, Boston, Massachusetts 02111, USA
Am J Kidney Dis 50:362-5. 2007 - Health utilities in Alzheimer's disease and implications for cost-effectiveness analysisPeter J Neumann
Department of Health Policy and Management and Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts, USA
Pharmacoeconomics 23:537-41. 2005..The NICE assumption that they do not results in a difference in utilities between dependent and non-dependent AD individuals of only 0.06. This seems to be at the low end of what one would consider a reasonable estimate... - Willingness to pay for avoiding coronary restenosis and repeat revascularization: results from a contingent valuation studyDan Greenberg
Harvard Clinical Research Institute, Boston, MA, USA
Health Policy 70:207-16. 2004..These findings may have important implications for emerging technologies such as drug-eluting stents... - Personalized medicine: factors influencing reimbursementLisa M Meckley
Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, 800 Washington St, 63, Boston, MA 02111, USA
Health Policy 94:91-100. 2010..Personalized medicine (PM) has attracted tremendous interest, but yielded few marketed products. We examined factors influencing the reimbursement of existing PM technologies... - A role for research: an observation on preventive services for womenNatalia Olchanski
Center for Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts 02111, USA
Am J Prev Med 44:S12-5. 2013..The Patient Protection and Affordable Care Act of 2010 (ACA) added preventive services for women, recommended by the IOM, to healthcare coverage requirements beginning in August 2011... - Imputing productivity gains from clinical trialsMichael J Cangelosi
Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, MA, USA
J Occup Environ Med 54:826-33. 2012..To respond to employer and payer interest in the extent to which productivity gains offset therapy costs by identifying clinical trials that did not include such measures and using their clinical data to impute productivity impact... - Cross-national comparison of technology assessment processesAnna García-Altés
Harvard School of Public Health, Boston, Massachusetts 02115, USA
Int J Technol Assess Health Care 20:300-10. 2004..To compare methods and results among four health technology assessment organizations in different countries... - Development and validation of a grading system for the quality of cost-effectiveness studiesChiun Fang Chiou
Zynx Health Inc, Cerner Corporation, Beverly Hills, California 90212, USA
Med Care 41:32-44. 2003..To provide a practical quantitative tool for appraising the quality of cost-effectiveness (CE) studies... - Bias in published cost effectiveness studies: systematic reviewChaim M Bell
St Michael s Hospital, Toronto, Ontario, Canada M5B 1W8
BMJ 332:699-703. 2006.... - Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force reportLouis P Garrison
University of Washington, Seattle, WA 98195, USA
Value Health 10:326-35. 2007.... - Budget impact analyses get some respectPeter J Neumann
Value Health 10:324-5. 2007 - What affects the quality of economic analysis for life-saving investments?Robert W Hahn
AEI Brookings Joint Center for Regulatory Studies, Washington, DC 20036, USA
Risk Anal 26:641-55. 2006..Somewhat surprisingly, a study's funding source and whether it is affiliated with industry are not significantly correlated with the quality index. Finally, neither time nor the panel guidelines had an impact on the index... - Biotechnology and Medicare's new technology policy: lessons from three case studiesPatricia Seliger Keenan
Division of Health Policy and Administration, Department of Epidemiology and Public Health, Yale University School of Medicine in New Haven, Connecticut, USA
Health Aff (Millwood) 25:1260-9. 2006..The cases suggest Medicare's ongoing challenge to balance access considerations, the role and strength of evidence, and cost consequences of new treatments... - Key principles for the improved conduct of health technology assessments for resource allocation decisionsMichael F Drummond
Centre for Health Economics, University of York, Heslington, York, UK
Int J Technol Assess Health Care 24:244-58; discussion 362-8. 2008..The principles are organized into four sections: (i) "Structure" of HTA programs; (ii) "Methods" of HTA; (iii) "Processes for Conduct" of HTA; and (iv) "Use of HTAs in Decision Making.".. - Diffusion of published cost-utility analyses in the field of health policy and practiceSeema S Sonnad
Department of Surgery, University of Pennsylvania, Philadelphia, Pennsylvania 19104 4283, USA
Int J Technol Assess Health Care 21:399-402. 2005..The diffusion of cost-utility analyses (CUAs) through the medical literature was examined, documenting visible patterns and determining how they correspond with expectations about the diffusion of process innovations... - Examining the value and quality of health economic analyses: implications of utilizing the QHESJoshua J Ofman
Zynx Health Inc, 9100 Wilshire Blvd, East Tower, Suite 655, Beverly Hills, CA 90212, USA
J Manag Care Pharm 9:53-61. 2003..To examine the increasing use of health economic studies and practical implications of evaluating their quality utilizing the Quality of Health Economic Studies (QHES) instrument... - Cost-effectiveness of topiramate in migraine prevention: results from a pharmacoeconomic model of topiramate treatmentJeffrey S Brown
Boston Health Economics, Inc, Waltham, MA 02451, USA
Headache 45:1012-22. 2005..However, results from our model suggest that the use of TPM in prevention of migraine may offer reasonable value for money relative to many well-accepted medical interventions... - Quality of abstracts of papers reporting original cost-effectiveness analysesAllison B Rosen
Division of General Medicine, University of Michigan Health Systems, Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor Veterans Affairs Medical Center, Ann Arbor, MI 48109, USA
Med Decis Making 25:424-8. 2005..The authors examined the extent to which abstracts of published CEAs include key data elements (intervention, comparator, target population, study perspective) and assessed the effect of journal characteristics on reporting quality... - A synthesis of cost-utility analysis literature in infectious diseasePatricia W Stone
Columbia University School of Nursing, New York, NY 10032, USA
Lancet Infect Dis 5:383-91. 2005..The results of cost-utility analyses have important implications for the development of clinical guidelines and resource allocation decisions. More trained investigators and better peer-review processes are needed... - Economic burden of pertussis and the impact of immunizationJ Jaime Caro
Caro Research Institute, Concord, MA 01742, USA
Pediatr Infect Dis J 24:S48-54. 2005..Despite the existing gaps in data, further research using the most current data should facilitate decisions on new vaccination strategies by describing conditions for favorable results and quantifying the margin of uncertainty... - The impact of Medicare modernization on coverage policy: recommendations for reformSusan Bartlett Foote
Division of Health Services Research and Policy, School of Public Health, University of Minnesota, Minneapolis, Minn 55455, USA
Am J Manag Care 11:140-2. 2005 - When is evidence sufficient?Karl Claxton
University of York, United Kingdom
Health Aff (Millwood) 24:93-101. 2005..Value-of-information analysis, a related methodology, helps to determine whether it is worthwhile to collect additional information as well as the type of research that would be most helpful... - Trends in cost effectiveness analyses in orthopaedic surgeryCarmen A Brauer
Department of Orthopaedic Surgery, British Columbia Children s Hospital, Vancouver, BC, Canada
Clin Orthop Relat Res 457:42-8. 2007....